A Phase I Trial of UCN-01 and Prednisone in Patients With Refractory Solid Tumors and Lymphomas

PURPOSE: UCN-01 potently inhibits protein kinase C, phosphatidylinositide-dependent kinase-1, and checkpoint kinase 1, which are involved in regulating cell cycle progression. We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kummar, Shivaani, Gutierrez, Martin E., Gardner, Erin R., Figg, William, Melillo, Giovanni, Dancey, Janet, Sausville, Edward A., Conley, Barbara A., Murgo, Anthony J., Doroshow, James H.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2854012/
https://ncbi.nlm.nih.gov/pubmed/19894051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-009-1154-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars